{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:58:36Z","timestamp":1792321116127,"version":"4.4.0"},"reference-count":200,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/ajg.2016.563","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T08:02:42Z","timestamp":1484035362000},"page":"212-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1354,"title":["ACG Clinical Guideline: Treatment of Helicobacter pylori Infection"],"prefix":"10.14309","volume":"112","author":[{"given":"William D","family":"Chey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios I","family":"Leontiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven F","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R2-12-20210210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00005176-200010000-00014","article-title":"Helicobacter pylori infection in children of Texas.","volume":"31","author":"Opekun","year":"2000","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R3-12-20210210","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1128\/CDLI.7.6.885-888.2000","article-title":"High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults.","volume":"7","author":"Parkinson","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"R4-12-20210210","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(02)08025-X","article-title":"Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood.","volume":"359","author":"Malaty","year":"2002","journal-title":"Lancet"},{"key":"R5-12-20210210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1083-4389.2004.00199.x","article-title":"The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission.","volume":"9","author":"Sinha","year":"2004","journal-title":"Helicobacter"},{"key":"R6-12-20210210","doi-asserted-by":"crossref","first-page":"e1000180","DOI":"10.1371\/journal.ppat.1000180","article-title":"Horizontal versus familial transmission of Helicobacter pylori.","volume":"4","author":"Schwarz","year":"2008","journal-title":"PLoS Pathog"},{"key":"R9-12-20210210","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ije\/dym201","article-title":"Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study.","volume":"36","author":"Ford","year":"2007","journal-title":"Int J Epidemiol"},{"key":"R10-12-20210210","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ajg.2008.61","article-title":"Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings.","volume":"104","author":"Weyermann","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R11-12-20210210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/10256010310001639868","article-title":"Helicobacter pylori determination in non-municipal drinking water and epidemiological findings.","volume":"40","author":"Krumbiegel","year":"2004","journal-title":"Isotopes Environ Health Stud"},{"key":"R12-12-20210210","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1007\/s10620-006-9210-5","article-title":"Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys.","volume":"51","author":"de Martel","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R13-12-20210210","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1155\/2007\/462804","article-title":"Helicobacter pylori infection in Ontario: prevalence and risk factors.","volume":"21","author":"Naja","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"R14-12-20210210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/hel.12199","article-title":"The prevalence of Helicobacter pylori remains high in African American and Hispanic veterans.","volume":"20","author":"Nguyen","year":"2015","journal-title":"Helicobacter"},{"key":"R15-12-20210210","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1086\/315384","article-title":"Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States.","volume":"181","author":"Everhart","year":"2000","journal-title":"J Infect Dis"},{"key":"R16-12-20210210","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10552-012-9960-7","article-title":"Neighborhood socio-economic characteristics, African ancestry, and Helicobacter pylori sero-prevalence.","volume":"23","author":"Epplein","year":"2012","journal-title":"Cancer Causes Control"},{"key":"R17-12-20210210","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/1055-9965.EPI-10-1258","article-title":"Race, African ancestry, and Helicobacter pylori infection in a low-income United States population.","volume":"20","author":"Epplein","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R18-12-20210210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1155\/2008\/258610","article-title":"Helicobacter pylori infection in Canadian and related Arctic Aboriginal populations.","volume":"22","author":"Goodman","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"R20-12-20210210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1023935701082","article-title":"Helicobacter pylori infection in pregnant women from a U.S.-Mexico border population.","volume":"5","author":"Goodman","year":"2003","journal-title":"J Immigr Health"},{"key":"R21-12-20210210","doi-asserted-by":"crossref","first-page":"e003689","DOI":"10.1136\/bmjopen-2013-003689","article-title":"Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns.","volume":"4","author":"Cheung","year":"2014","journal-title":"BMJ Open"},{"key":"R22-12-20210210","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1007\/s10620-014-3063-0","article-title":"Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage.","volume":"59","author":"Peleteiro","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R23-12-20210210","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s11606-013-2630-y","article-title":"Helicobacter pylori: evidence-based review with a focus on immigrant populations.","volume":"29","author":"Siao","year":"2014","journal-title":"J Gen Intern Med"},{"key":"R24-12-20210210","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jurban\/jti093","article-title":"Seroprevalence of Helicobacter pylori in New York City populations originating in East Asia.","volume":"82","author":"Perez-Perez","year":"2005","journal-title":"J Urban Health"},{"key":"R25-12-20210210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/aje\/kwi207","article-title":"Helicobacter pylori infection in different generations of Hispanics in the San Francisco Bay Area.","volume":"162","author":"Tsai","year":"2005","journal-title":"Am J Epidemiol"},{"key":"R26-12-20210210","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"American College of Gastroenterology guideline on the management of Helicobacter pylori infection.","volume":"102","author":"Chey","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R27-12-20210210","first-page":"0406","article-title":"Helicobacter pylori infection.","volume":"10","author":"Leontiadis","year":"2009","journal-title":"BMJ Clinical Evidence"},{"key":"R28-12-20210210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","article-title":"Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.","volume":"61","author":"Nakamura","year":"2012","journal-title":"Gut"},{"key":"R30-12-20210210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/01.cco.0000432523.24358.15","article-title":"The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach.","volume":"25","author":"Ferreri","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"R31-12-20210210","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3346\/jkms.2015.30.6.749","article-title":"Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer.","volume":"30","author":"Bang","year":"2015","journal-title":"J Korean Med Sci"},{"key":"R32-12-20210210","doi-asserted-by":"crossref","first-page":"e0124725","DOI":"10.1371\/journal.pone.0124725","article-title":"Jung, da H, Kim JH, Chung HS et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis.","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"R33-12-20210210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/hel.12146","article-title":"Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis.","volume":"19","author":"Yoon","year":"2014","journal-title":"Helicobacter"},{"key":"R35-12-20210210","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2036.2010.04363.x","article-title":"Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultationsthe Bristol Helicobacter Project.","volume":"32","author":"Harvey","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-12-20210210","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2036.2008.03784.x","article-title":"Meta-analysis: Helicobacter pyloritest and treat compared with empirical acid suppression for managing dyspepsia.","volume":"28","author":"Ford","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-12-20210210","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1053\/j.gastro.2005.03.004","article-title":"Helicobacter pylori test and treat or endoscopy for managing dyspepsia: an individual patient data meta-analysis.","volume":"128","author":"Ford","year":"2005","journal-title":"Gastroenterology"},{"key":"R40-12-20210210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrgastro.2013.9","article-title":"Helicobacter pylori infection in functional dyspepsia.","volume":"10","author":"Suzuki","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R41-12-20210210","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1053\/j.gastro.2016.02.011","article-title":"Gastroduodenal disorders.","volume":"150","author":"Stanghellini","year":"2016","journal-title":"Gastroenterology"},{"key":"R42-12-20210210","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1053\/j.gastro.2015.07.039","article-title":"American Gastroenterological Association Institute Guideline on the role of upper gastrointestinal biopsy to evaluate dyspepsia in the adult patient in the absence of visible mucosal lesions.","volume":"149","author":"Yang","year":"2015","journal-title":"Gastroenterology"},{"key":"R44-12-20210210","doi-asserted-by":"crossref","first-page":"985249","DOI":"10.1155\/2015\/985249","article-title":"Helicobacter pylori infection in gastroesophageal reflux disease in the Asian Countries.","volume":"2015","author":"Hong","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"R45-12-20210210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4291\/wjgp.v5.i3.178","article-title":"Barretts oesophagus: evidence from the current meta-analyses.","volume":"5","author":"Gatenby","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"R46-12-20210210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.2006.02964.x","article-title":"Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia.","volume":"24","author":"Vakil","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R47-12-20210210","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1111\/j.1572-0241.2002.07116.x","article-title":"Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.","volume":"97","author":"Laine","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R48-12-20210210","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/bmj.38082.626725.EE","article-title":"Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project.","volume":"328","author":"Harvey","year":"2004","journal-title":"Bmj"},{"key":"R49-12-20210210","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2004.02172.x","article-title":"Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis.","volume":"20","author":"Raghunath","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R50-12-20210210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000090955","article-title":"Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study.","volume":"52","author":"Pilotto","year":"2006","journal-title":"Gerontology"},{"key":"R51-12-20210210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/2050640613484020","article-title":"The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study.","volume":"1","author":"Schwizer","year":"2013","journal-title":"United European Gastroenterol J"},{"key":"R52-12-20210210","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4103\/0366-6999.155049","article-title":"Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study.","volume":"128","author":"Xue","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"R53-12-20210210","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM199604183341603","article-title":"Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.","volume":"334","author":"Kuipers","year":"1996","journal-title":"N Engl J Med"},{"key":"R54-12-20210210","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1523-5378.2000.00032.x","article-title":"Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.","volume":"5","author":"Moayyedi","year":"2000","journal-title":"Helicobacter"},{"key":"R55-12-20210210","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infectionthe Maastricht IV Florence Consensus Report.","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"R56-12-20210210","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCFACGAHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R57-12-20210210","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2036.2002.01230.x","article-title":"Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin.","volume":"16","author":"Lanas","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R58-12-20210210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2036.2002.01197.x","article-title":"Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding.","volume":"16","author":"Stack","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R59-12-20210210","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","article-title":"Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin.","volume":"22","author":"Yeomans","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R60-12-20210210","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/j.gastro.2012.12.038","article-title":"Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users.","volume":"144","author":"Chan","year":"2013","journal-title":"Gastroenterology"},{"key":"R61-12-20210210","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/ajg.2010.445","article-title":"ACCFACGAHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCFACGAHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.","volume":"105","author":"Abraham","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R62-12-20210210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(02)07273-2","article-title":"Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.","volume":"359","author":"Huang","year":"2002","journal-title":"Lancet"},{"key":"R63-12-20210210","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications.","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R64-12-20210210","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(97)04523-6","article-title":"Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.","volume":"350","author":"Chan","year":"1997","journal-title":"Lancet"},{"key":"R65-12-20210210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(02)07272-0","article-title":"Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.","volume":"359","author":"Chan","year":"2002","journal-title":"Lancet"},{"key":"R66-12-20210210","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1365-2036.2005.02444.x","article-title":"Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.","volume":"21","author":"Vergara","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R68-12-20210210","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1365-2036.2003.01528.x","article-title":"Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial.","volume":"17","author":"Lai","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R69-12-20210210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1523-5378.2007.00543.x","article-title":"Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial.","volume":"12","author":"de Leest","year":"2007","journal-title":"Helicobacter"},{"key":"R70-12-20210210","first-page":"886","article-title":"Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis.","volume":"16","author":"Qu","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R71-12-20210210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1017\/S0007114511005666","article-title":"Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention effects by H. pylori eradication.","volume":"108","author":"Xia","year":"2012","journal-title":"Br J Nutr"},{"key":"R72-12-20210210","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.3748\/wjg.v13.i40.5380","article-title":"Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis.","volume":"13","author":"Chen","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R73-12-20210210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/00365521003663670","article-title":"Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials.","volume":"45","author":"Yuan","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"R75-12-20210210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ajh.20250","article-title":"Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature.","volume":"78","author":"Jackson","year":"2005","journal-title":"Am J Hematol"},{"key":"R76-12-20210210","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1572-0241.2005.41641.x","article-title":"Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial.","volume":"100","author":"Suzuki","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R77-12-20210210","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00277-005-1071-z","article-title":"Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.","volume":"84","author":"Tsutsumi","year":"2005","journal-title":"Ann Hematol"},{"key":"R78-12-20210210","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1651-2227.2003.tb02476.x","article-title":"Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura.","volume":"92","author":"Jaing","year":"2003","journal-title":"Acta Paediatr"},{"key":"R79-12-20210210","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-07-167155","article-title":"Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review.","volume":"113","author":"Stasi","year":"2009","journal-title":"Blood"},{"key":"R80-12-20210210","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"R81-12-20210210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000280318","article-title":"Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis.","volume":"83","author":"Wang","year":"2011","journal-title":"Digestion"},{"key":"R82-12-20210210","doi-asserted-by":"crossref","first-page":"g3174","DOI":"10.1136\/bmj.g3174","article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials.","volume":"348","author":"Ford","year":"2014","journal-title":"BMJ"},{"key":"R83-12-20210210","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/archinte.159.9.925","article-title":"Non-gastrointestinal tract associations of Helicobacter pylori infection.","volume":"159","author":"Leontiadis","year":"1999","journal-title":"Arch Intern Med"},{"key":"R84-12-20210210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2036.2006.02778.x","article-title":"Healing of lymphocytic gastritis after Helicobacter pylori eradication therapya randomized, double-blind, placebo-controlled multicentre trial.","volume":"23","author":"Madisch","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R85-12-20210210","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3748\/wjg.v12.i11.1770","article-title":"Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.","volume":"12","author":"Ji","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R86-12-20210210","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/MCG.0000000000000108","article-title":"Does H. pylori eradication therapy benefit patients with hepatic encephalopathy? systematic review.","volume":"48","author":"Schulz","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"R87-12-20210210","doi-asserted-by":"crossref","first-page":"278905","DOI":"10.1155\/2015\/278905","article-title":"Helicobacter pylori infection is associated with an increased risk of hyperemesis gravidarum: a meta-analysis.","volume":"2015","author":"Li","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"R88-12-20210210","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00392-014-0720-4","article-title":"Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.","volume":"103","author":"Budzynski","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"R90-12-20210210","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/ACI.0b013e32833c79d7","article-title":"Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the grading of recommendations assessment, development, and evaluation system.","volume":"10","author":"Shakouri","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R91-12-20210210","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.3748\/wjg.v21.i17.5407","article-title":"Is Helicobacter pylori infection associated with glycemic control in diabetics?","volume":"21","author":"Dai","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R92-12-20210210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/apt.12790","article-title":"Review article: associations between Helicobacter pylori and obesityan ecological study.","volume":"40","author":"Lender","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R93-12-20210210","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00042737-200306000-00010","article-title":"Reduced risk of atopic disorders in adults with Helicobacter pylori infection.","volume":"15","author":"McCune","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R94-12-20210210","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/cea.12404","article-title":"Is Helicobacter pylori infection inversely associated with atopy? A systematic review and meta-analysis.","volume":"45","author":"Taye","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"R95-12-20210210","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2011.06.081","article-title":"Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database.","volume":"141","author":"Dellon","year":"2011","journal-title":"Gastroenterology"},{"key":"R96-12-20210210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/hel.12129","article-title":"Does Helicobacter pylori protect against eosinophilic esophagitis in children?","volume":"19","author":"Elitsur","year":"2014","journal-title":"Helicobacter"},{"key":"R97-12-20210210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3164\/jcbn.13-15","article-title":"Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan.","volume":"53","author":"Furuta","year":"2013","journal-title":"J Clin Biochem Nutr"},{"key":"R98-12-20210210","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/gut.2006.107714","article-title":"Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study.","volume":"56","author":"Ronkainen","year":"2007","journal-title":"Gut"},{"key":"R99-12-20210210","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/apt.13560","article-title":"Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis.","volume":"43","author":"von Armin","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R100-12-20210210","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0016-5085(14)61444-X","article-title":"Su1198 Community H. pylori Project Treatment Trial results from the Canadian Arctic.","volume":"146","author":"Van Zanten","year":"2014","journal-title":"Gastroenterology"},{"key":"R101-12-20210210","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/aje\/kwt234","article-title":"Decreased risk of celiac disease in patients with Helicobacter pylori colonization.","volume":"178","author":"Lebwohl","year":"2013","journal-title":"Am J Epidemiol"},{"key":"R102-12-20210210","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/2050640615580889","article-title":"The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis.","volume":"3","author":"Rokkas","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"R103-12-20210210","doi-asserted-by":"crossref","first-page":"h4052","DOI":"10.1136\/bmj.h4052","article-title":"Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.","volume":"351","author":"Li","year":"2015","journal-title":"BMJ"},{"key":"R104-12-20210210","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0016-5085(14)61441-4","article-title":"Sequential therapy is not better at eradication of primary Helicobacter pylori infection when compared to standard triple therapy in the United States-a prospective, randomized evaluation in a United States population.","volume":"146","author":"Coss","year":"2014","journal-title":"Gastroenterology"},{"key":"R105-12-20210210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2013\/801915","article-title":"Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada.","volume":"27","author":"Fallone","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"R106-12-20210210","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/ajg.2011.306","article-title":"A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.","volume":"106","author":"Basu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R107-12-20210210","first-page":"214","article-title":"Randomized controlled trial comparing proton pump inhibitor-based eradication regimens versus low-cost eradication regimen for patients with Helicobacter pylori with uninvestigated dyspepsia.","volume":"6","author":"Chen","year":"2006","journal-title":"J App Res"},{"key":"R108-12-20210210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2036.2004.02029.x","article-title":"Seven-day therapy for Helicobacter pylori in the United States.","volume":"20","author":"Vakil","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R109-12-20210210","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1523-5378.2003.00179.x","article-title":"Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.","volume":"8","author":"Bochenek","year":"2003","journal-title":"Helicobacter"},{"key":"R110-12-20210210","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/S0002-9270(03)00432-5","article-title":"Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.","volume":"98","author":"Veldhuyzen van Zanten","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R111-12-20210210","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1001\/archinte.163.17.2079","article-title":"One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.","volume":"163","author":"Lara","year":"2003","journal-title":"Arch Intern Med"},{"key":"R112-12-20210210","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1572-0241.2003.t01-1-07288.x","article-title":"Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.","volume":"98","author":"Laine","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R113-12-20210210","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1111\/j.1572-0241.2002.06036.x","article-title":"Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.","volume":"97","author":"Sullivan","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R114-12-20210210","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/bmj.324.7344.1012","article-title":"Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.","volume":"324","author":"Chiba","year":"2002","journal-title":"Bmj"},{"key":"R115-12-20210210","first-page":"92","article-title":"Helicobacter pylori eradication in dyspeptic primary care patients: a randomized controlled trial of a pharmacy intervention.","volume":"176","author":"Stevens","year":"2002","journal-title":"West J Med"},{"key":"R116-12-20210210","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1523-5378.2000.00030.x","article-title":"The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.","volume":"5","author":"Bardhan","year":"2000","journal-title":"Helicobacter"},{"key":"R117-12-20210210","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1046\/j.1365-2036.2000.00911.x","article-title":"One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.","volume":"14","author":"Veldhuyzen Van Zanten","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R118-12-20210210","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1155\/2000\/690307","article-title":"Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study.","volume":"14","author":"Veldhuyzen Van Zanten","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"R119-12-20210210","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1111\/j.1572-0241.2000.03349.x","article-title":"Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials.","volume":"95","author":"Laine","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R120-12-20210210","first-page":"CD008337","article-title":"Optimum duration of regimens for Helicobacter pylori eradication.","volume":"12","author":"Yuan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R121-12-20210210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ajg.2009.508","article-title":"Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.","volume":"105","author":"Luther","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R122-12-20210210","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.cgh.2015.02.005","article-title":"Antibiotic resistance of Helicobacter pylori among male United States veterans.","volume":"13","author":"Shiota","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R123-12-20210210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/0003-4819-139-6-200309160-00008","article-title":"The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections.","volume":"139","author":"McMahon","year":"2003","journal-title":"Ann Intern Med"},{"key":"R124-12-20210210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"R125-12-20210210","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-2036.2012.05083.x","article-title":"Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?","volume":"35","author":"McNulty","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R126-12-20210210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.dld.2015.12.001","article-title":"The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use.","volume":"48","author":"Lim","year":"2016","journal-title":"Dig Liver Dis"},{"key":"R127-12-20210210","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000350719","article-title":"Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.","volume":"88","author":"Venerito","year":"2013","journal-title":"Digestion"},{"key":"R128-12-20210210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1523-5378.1998.08019.x","article-title":"Amoxicillinmetronidazoleomeprazoleclarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication.","volume":"3","author":"Treiber","year":"1998","journal-title":"Helicobacter"},{"key":"R129-12-20210210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CEG.S25419","article-title":"Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.","volume":"5","author":"Gisbert","year":"2012","journal-title":"Clin Exp Gastroenterol"},{"key":"R130-12-20210210","doi-asserted-by":"crossref","first-page":"f4587","DOI":"10.1136\/bmj.f4587","article-title":"Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.","volume":"347","author":"Gatta","year":"2013","journal-title":"Bmj"},{"key":"R131-12-20210210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(11)60825-8","article-title":"14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.","volume":"378","author":"Greenberg","year":"2011","journal-title":"Lancet"},{"key":"R132-12-20210210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2036.2000.00766.x","article-title":"A new highly effective short-term therapy schedule for Helicobacter pylori eradication.","volume":"14","author":"Zullo","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R134-12-20210210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","article-title":"Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.","volume":"381","author":"Liou","year":"2013","journal-title":"Lancet"},{"key":"R135-12-20210210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1523-5378.2011.00828.x","article-title":"Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.","volume":"16","author":"Hsu","year":"2011","journal-title":"Helicobacter"},{"key":"R136-12-20210210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/hel.12180","article-title":"Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis.","volume":"20","author":"Wang","year":"2015","journal-title":"Helicobacter"},{"key":"R137-12-20210210","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2169\/internalmedicine.54.3442","article-title":"Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication.","volume":"54","author":"He","year":"2015","journal-title":"Intern Med"},{"key":"R138-12-20210210","doi-asserted-by":"crossref","first-page":"e85620","DOI":"10.1371\/journal.pone.0085620","article-title":"Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials.","volume":"9","author":"Peedikayil","year":"2014","journal-title":"PLoS One"},{"key":"R139-12-20210210","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/00365521.2014.887765","article-title":"Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis.","volume":"49","author":"Xiao","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"R140-12-20210210","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/phar.1614","article-title":"Fluoroquinolone sequential therapy for Helicobacter pylori: a meta-analysis.","volume":"35","author":"Kale-Pradhan","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R141-12-20210210","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1128\/JCM.01067-11","article-title":"Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008.","volume":"49","author":"Tveit","year":"2011","journal-title":"J Clin Microbiol"},{"key":"R142-12-20210210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1155\/2015\/853287","article-title":"Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario.","volume":"26","author":"Eng","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"R143-12-20210210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MCG.0b013e318266f6cf","article-title":"Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy.","volume":"47","author":"Wang","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"R144-12-20210210","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.3748\/wjg.v21.i14.4345","article-title":"Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis.","volume":"21","author":"Zhang","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"R145-12-20210210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0016-5085(92)90095-G","article-title":"Factors influencing the eradication of Helicobacter pylori with triple therapy.","volume":"102","author":"Graham","year":"1992","journal-title":"Gastroenterology"},{"key":"R146-12-20210210","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1592\/phco.19.4.324.30939","article-title":"Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis.","volume":"19","author":"Buring","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R147-12-20210210","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1001\/archinte.159.19.2312","article-title":"A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.","volume":"159","author":"Lee","year":"1999","journal-title":"Arch Intern Med"},{"key":"R148-12-20210210","doi-asserted-by":"crossref","first-page":"e62162","DOI":"10.1371\/journal.pone.0062162","article-title":"Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.","volume":"8","author":"Tang","year":"2013","journal-title":"PLoS One"},{"key":"R149-12-20210210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjmed.2005.10.003","article-title":"Smoking increases the treatment failure for Helicobacter pylori eradication.","volume":"119","author":"Suzuki","year":"2006","journal-title":"Am J Med"},{"key":"R150-12-20210210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.diabres.2014.07.009","article-title":"High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis.","volume":"106","author":"Horikawa","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"R151-12-20210210","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1023\/A:1005457226341","article-title":"Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.","volume":"45","author":"Dore","year":"2000","journal-title":"Dig Dis Sci"},{"key":"R152-12-20210210","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","article-title":"Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.","volume":"26","author":"Fischbach","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R154-12-20210210","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkp034","article-title":"Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.","volume":"63","author":"Kuo","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R155-12-20210210","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.dld.2007.06.016","article-title":"Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.","volume":"39","author":"Perna","year":"2007","journal-title":"Dig Liver Dis"},{"key":"R156-12-20210210","doi-asserted-by":"crossref","first-page":"9912","DOI":"10.3748\/wjg.v20.i29.9912","article-title":"Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.","volume":"20","author":"Smith","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R157-12-20210210","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ajg.2014.24","article-title":"The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.","volume":"109","author":"Camargo","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R158-12-20210210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance.","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R159-12-20210210","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3201\/eid1006.030744","article-title":"Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States.","volume":"10","author":"Duck","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"R160-12-20210210","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJMc1212055","article-title":"U.S. outpatient antibiotic prescribing, 2010.","volume":"368","author":"Hicks","year":"2013","journal-title":"N Engl J Med"},{"key":"R161-12-20210210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fmolb.2014.00019","article-title":"Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.","volume":"1","author":"Nishizawa","year":"2014","journal-title":"Front Mol Biosci"},{"key":"R162-12-20210210","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/jac\/dkv155","article-title":"Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection.","volume":"70","author":"Lopez-Gongora","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R163-12-20210210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cgh.2012.12.007","article-title":"Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.","volume":"11","author":"Fiorini","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R164-12-20210210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/jac\/dks407","article-title":"Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.","volume":"68","author":"Liou","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R165-12-20210210","first-page":"417","article-title":"Pan-European Registry on H. pylori Management (HP-EuReg): Bacterial Resistance.","volume":"148","author":"McNicholl","year":"2015","journal-title":"Gastroenterology"},{"key":"R166-12-20210210","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1572-0241.2000.02005.x","article-title":"Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection.","volume":"95","author":"Chey","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R167-12-20210210","doi-asserted-by":"crossref","first-page":"547","DOI":"10.7326\/0003-4819-129-7-199810010-00007","article-title":"Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.","volume":"129","author":"Laine","year":"1998","journal-title":"Ann Intern Med"},{"key":"R168-12-20210210","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/j.1572-0241.2002.05904.x","article-title":"The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage.","volume":"97","author":"Ofman","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R169-12-20210210","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2036.2005.02569.x","article-title":"Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment?","volume":"22","author":"Pohl","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R170-12-20210210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2036.2000.00735.x","article-title":"Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcersa cost-effectiveness analysis.","volume":"14","author":"Gene","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R171-12-20210210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-230X-7-31","article-title":"Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection.","volume":"7","author":"Navarro-Jarabo","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"R172-12-20210210","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14656566.2013.782286","article-title":"A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).","volume":"14","author":"Marin","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R173-12-20210210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1523-5378.2011.00844.x","article-title":"Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.","volume":"16","author":"Chung","year":"2011","journal-title":"Helicobacter"},{"key":"R174-12-20210210","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1523-5378.2011.00870.x","article-title":"Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.","volume":"16","author":"Lee","year":"2011","journal-title":"Helicobacter"},{"key":"R175-12-20210210","first-page":"330","article-title":"Prospective, randomized study of seven versus fourteen days omeprazole quadruple therapy for eradication of Helicobacter pylori infection in patients with duodenal ulcer after failure of omeprazole triple therapy.","volume":"18","author":"Mantzaris","year":"2005","journal-title":"Ann Gastroenterol"},{"key":"R176-12-20210210","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1365-2036.2003.01676.x","article-title":"Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.","volume":"18","author":"Nista","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R177-12-20210210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000050674","article-title":"A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.","volume":"19","author":"Magaret","year":"2001","journal-title":"Dig Dis"},{"key":"R178-12-20210210","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1523-5378.2003.00158.x","article-title":"A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.","volume":"8","author":"Miehlke","year":"2003","journal-title":"Helicobacter"},{"key":"R179-12-20210210","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3109\/00365521.2015.1037345","article-title":"Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.","volume":"50","author":"Cao","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"R180-12-20210210","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-230X-13-138","article-title":"Long-term follow up Helicobacter pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.","volume":"13","author":"Kim","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"R181-12-20210210","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1523-5378.2012.00960.x","article-title":"The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacinamoxicillinproton-pump inhibitor treatmenta pilot study.","volume":"17","author":"Chuah","year":"2012","journal-title":"Helicobacter"},{"key":"R182-12-20210210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1523-5378.2009.00735.x","article-title":"Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.","volume":"15","author":"Lee","year":"2010","journal-title":"Helicobacter"},{"key":"R183-12-20210210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1440-1746.2007.04984.x","article-title":"Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.","volume":"23","author":"Uygun","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R184-12-20210210","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1523-5378.2007.00548.x","article-title":"Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.","volume":"12","author":"Kang","year":"2007","journal-title":"Helicobacter"},{"key":"R185-12-20210210","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1542-3565(04)00458-6","article-title":"A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial.","volume":"2","author":"Bilardi","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R186-12-20210210","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.dld.2008.09.013","article-title":"Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.","volume":"41","author":"Di Caro","year":"2009","journal-title":"Dig Liver Dis"},{"key":"R187-12-20210210","first-page":"263","article-title":"Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection.","volume":"22","author":"Karatapanis","year":"2009","journal-title":"Annals of Gastroenterology"},{"key":"R188-12-20210210","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/j.1365-2036.2012.05117.x","article-title":"Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection.","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R189-12-20210210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4318\/tjg.2010.0041","article-title":"Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.","volume":"21","author":"Ercin","year":"2010","journal-title":"Turk J Gastroenterol"},{"key":"R190-12-20210210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1523-5378.2007.00507.x","article-title":"Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.","volume":"12","author":"Cheng","year":"2007","journal-title":"Helicobacter"},{"key":"R191-12-20210210","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10620-014-3365-2","article-title":"Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.","volume":"60","author":"Gisbert","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R192-12-20210210","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2169\/internalmedicine.53.1677","article-title":"Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.","volume":"53","author":"Furuta","year":"2014","journal-title":"Intern Med"},{"key":"R193-12-20210210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1523-5378.2009.00664.x","article-title":"Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.","volume":"14","author":"Ueki","year":"2009","journal-title":"Helicobacter"},{"key":"R194-12-20210210","doi-asserted-by":"crossref","first-page":"163960","DOI":"10.1155\/2015\/163960","article-title":"Comparison of second-line quadruple therapies with or without bismuth for Helicobacter pylori infection.","volume":"2015","author":"Jheng","year":"2015","journal-title":"Biomed Res Int"},{"key":"R195-12-20210210","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1523-5378.2011.00842.x","article-title":"Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the japanese population.","volume":"16","author":"Hori","year":"2011","journal-title":"Helicobacter"},{"key":"R198-12-20210210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2036.2002.01173.x","article-title":"High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.","volume":"16","author":"Peitz","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R199-12-20210210","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1365-2036.2003.01759.x","article-title":"Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies.","volume":"18","author":"Lamouliatte","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R200-12-20210210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R201-12-20210210","doi-asserted-by":"crossref","first-page":"415648","DOI":"10.1155\/2015\/415648","article-title":"Rescue therapy with a proton pump inhibitor plus amoxicillin and rifabutin for Helicobacter pylori infection: a systematic review and meta-analysis.","volume":"2015","author":"Liu","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"R202-12-20210210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/hel.12147","article-title":"Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori.","volume":"19","author":"Lim","year":"2014","journal-title":"Helicobacter"},{"key":"R203-12-20210210","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2036.2006.02993.x","article-title":"Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.","volume":"24","author":"Miehlke","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R204-12-20210210","first-page":"58","article-title":"Randomized study of two rescue therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.","volume":"96","author":"Perri","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R205-12-20210210","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/bega.2001.0188","article-title":"Current role of acid suppressants in Helicobacter pylori eradication therapy.","volume":"15","author":"Labenz","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R207-12-20210210","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1111\/j.1440-1746.2008.05407.x","article-title":"Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.","volume":"23","author":"Nishizawa","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R208-12-20210210","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00535-012-0731-8","article-title":"Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.","volume":"48","author":"Murakami","year":"2013","journal-title":"J Gastroenterol"},{"key":"R209-12-20210210","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00228-007-0302-8","article-title":"Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.","volume":"63","author":"Shirai","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R210-12-20210210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4166\/kjg.2015.66.5.261","article-title":"Ten-day sequential therapy versus bismuth based quadruple therapy as second line treatment for Helicobacter pylori infection.","volume":"66","author":"Kim","year":"2015","journal-title":"Korean J Gastroenterol"},{"key":"R211-12-20210210","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1046\/j.1365-2036.2002.01299.x","article-title":"Furazolidone-based triple rescue therapy vs. quadruple rescue therapy for the eradication of Helicobacter pylori resistant to metronidazole.","volume":"16","author":"Isakov","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R212-12-20210210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2036.2004.02210.x","article-title":"Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.","volume":"21","author":"Qasim","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R213-12-20210210","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.12089","article-title":"Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.","volume":"36","author":"Tay","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R214-12-20210210","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ACI.0000000000000173","article-title":"Penicillin allergy: optimizing diagnostic protocols, public health implications, and future research needs.","volume":"15","author":"Macy","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R216-12-20210210","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.gtc.2015.05.013","article-title":"Current status and prospects for a Helicobacter pylori vaccine.","volume":"44","author":"Blanchard","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"R217-12-20210210","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"386","author":"Zeng","year":"2015","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1038\/s41395-018-0132-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000}}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2016563.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016563","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016563.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201702000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:15:00Z","timestamp":1786547700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201702000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":200,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2016.563","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727191551.793546695","asserted-by":"object"}]},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}